Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
About this episode
Cheryl Lai interviews Professor Fred Saad about the quality of life outcomes in patients with metastatic hormone-sensitive prostate cancer from the ARANOTE trial.
Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext
More episodes of The Lancet Oncology in conversation with
- James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
- Ali Landman on the European Congress of Radiology 2026
- Kayleigh Bhangdia on breast cancer GBD study 2023
- Dylan Graetz and Erica Kaye on qualitative research in oncology
- Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers
- Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3
Explore listener stats, chart rankings, contacts and more on the The Lancet Oncology in conversation with podcast page.